News & Updates 2018-08-27T16:12:11+00:00

News & Updates

Canadian Rheumatology Association Position Statement on Medical Cannabis Use in Rheumatic Disease

With the legalization of cannabis on October 17, 2018, Canadians may increasingly turn to their physicians for guidance regarding medical cannabis use, which has already entered mainstream medicine.

In the absence of studies examining the effects of medical cannabis in patients with rheumatic diseases, a position statement has been developed and published in the to help rheumatologists to offer pragmatic advice to their patient in a caring and empathetic way to ensure harm reduction. It was published online in The Journal of Rheumatology.

A copy of the statement can be found here.

Introducing the Arthritis Health Professions Association

AHPA Logo

Do you know or work with health professionals who want to stay current with evidence-based knowledge in the field of rheumatology and arthritis care? If so, please pass along this message!

The Arthritis Health Professions Association (AHPA) is a Canadian organization with a mission to build and sustain a community of professionals who provides the best possible care to Canadians with arthritis through knowledge translation, engagement, and inter-professional collaboration.

Membership benefits include a monthly newsletter, continuing education events, webinars, conferences, and other opportunities to share knowledge and expertise at an inter- professional level in the field of rheumatology. Members may apply for research grants and awards, attend the annual CRA/AHPA Annual Scientific Meeting and network with experts in the field of rheumatology. Travel bursaries are available to help offset costs.

Visit www.ahpa.ca to for more information.

Triamcinolone Hexacetonide Supply Update

Medexus has announced that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (Intra-Articular/Periarticular/Intrasynovial Injection) is now available in Canada.

Indication:
Triamcinolone Hexacetonide (TH) Injectable Suspension is indicated for intra-articular, intrasynovial, or periarticular use in adults and adolescents for the symptomatic treatment of subacute and chronic inflammatory joint diseases including:

  • Rheumatoid arthritis
  • Juvenile Idiopathic Arthritis (JIA)
  • Osteoarthritis and post-traumatic arthritis
  • Synovitis, tendinitis, bursitis and epicondylitis

Geriatrics (over 65 years of age):
No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects.  Reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.

Pediatrics (3-12 years of age):
Triamcinolone Hexacetonide Injectable Suspension may be used as an intra-articular injection in children aged 3-12 years with Juvenile Idiopathic Arthritis (see WARNINGS AND PRECAUTIONS – Special Populations, and DOSAGE AND ADMINISTRATION).

Availability:   
October 9, 2018  
Triamcinolone Hexacetonide (TH) is available at all wholesalers and can be ordered by any pharmacy.

Package:
Each carton contains 10 ampoules

More information can be obtained via the following links:
Product monograph
Local contact information

CRA (CIORA)-Arthritis Society Clinician Investigator Award

The grant recipient for the 2018 CRA (CIORA) Arthritis Society Clinician Investigator Salary Award is Dr. Zahi Touma for his research on describing different types of cognitive impairment in lupus patients using a combination of novel advanced brain imaging techniques and specified cognitive tests.

Dr. Touma explains that “this award is very essential to protect my research time and to continue developing my research program.  I am very thankful and privileged to receive the CRA (CIORA)-Arthritis Society Clinician Investigator Award which is going to allow me to pursue my academic career”

For more information on the CRA (CIORA)-Arthritis Society Clinician Investigator Award go to rheum.ca/research/cra-ciora-tas-clinician-investigator/.

New SLE Recommendations

As an Initiative of the Canadian Rheumatology Association, the Canadian SLE Working Group developed novel recommendations for the assessment and monitoring of systemic lupus erythematosus (SLE) using GRADE (Grading of Recommendations, Assessment, Development and Evaluation).   Strong recommendations are made for cardiovascular risk assessment, annual influenza vaccination, and the measurement of anti-Ro and antiLa in the peripartum period while conditional recommendations are made for using validated measures of disease activity and damage, peripartum assessments, evaluation of osteoporosis and osteonecrosis, and screening for hepatitis B and C. This work has identified future areas of research and consideration for future therapeutic recommendations.

Read More…

Myochrysine Supply Update – August 10, 2018

The CRA has been informed by Sanofi-Genzyme that their limited supply of 10mg/mL dosage format has now been exhausted.  Sanofi-Genzyme is looking for solutions to resolve this supply issue, the expected return date is September 2019.

The CRA will keep you updated as information becomes available.

Drug Shortages Canada